Compared to control group was administered placebo what was the result of Microencapsulated sodium butyrate (MSB) 300 mg daily on Subjective improvement in observed symptoms based on a single closed-end question (yes or no answer): “Did you observe adequate relief of diverticulosis related to abdominal pain or discomfort within the past 12&nbsp;months?”?
The number of diverticulitis clinical symptom occurrences during 12 months of observation was 2 (6.67 %) in the MSB group and was significantly lower (p = 0.0425) than the clinical symptoms of diverticulitis reported in the control group (7 occurrences, 31.8 %).